Patents Assigned to International AIDS Vaccine Initiative, Inc.
-
Patent number: 11891416Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: October 19, 2020Date of Patent: February 6, 2024Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
-
Patent number: 11845789Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: July 15, 2021Date of Patent: December 19, 2023Assignees: THERACLONE SCIENCES, INC., THE SCRIPPS RESEARCH INSTITUTE, INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
-
Patent number: 11834669Abstract: Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: July 1, 2021Date of Patent: December 5, 2023Assignees: International AIDS Vaccine Initiative, Inc., Oregon Health and Science UniversityInventors: Thomas G. Evans, Ravi Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
-
Patent number: 11787842Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: April 21, 2021Date of Patent: October 17, 2023Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker
-
Patent number: 11692014Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: August 15, 2019Date of Patent: July 4, 2023Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
-
Patent number: 11667930Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: GrantFiled: December 17, 2019Date of Patent: June 6, 2023Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventors: Christopher L. Parks, Maoli Yuan, Kevin Wright, Christy Jurgens
-
Patent number: 11638749Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: October 15, 2018Date of Patent: May 2, 2023Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Dominick Laddy, Danilo Casimiro, Thomas Evans, Megan Fitzpatrick Forrest, Nathalie Cadieux
-
Patent number: 11584789Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: October 28, 2020Date of Patent: February 21, 2023Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, INC., THE SCRIPPS RESEARCH INSTITUTE, THERACLONE SCIENCES, INC.Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Patent number: 11446373Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.Type: GrantFiled: July 2, 2020Date of Patent: September 20, 2022Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Tom Jin, Eric I-Fu Tsao
-
Publication number: 20210338804Abstract: The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.Type: ApplicationFiled: February 19, 2021Publication date: November 4, 2021Applicants: International AIDS Vaccine Initiative Inc., Merck Sharp & Dohme Corp.Inventors: Christopher Lee Parks, Maoli Yuan, Mark Feinberg, Amy Espeseth, Andrew J. Bett
-
Patent number: 11014969Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: March 1, 2019Date of Patent: May 25, 2021Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker
-
Patent number: 10736953Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.Type: GrantFiled: January 2, 2019Date of Patent: August 11, 2020Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Tom Jin, Eric I-Fu Tsao
-
Patent number: 10428122Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: June 16, 2017Date of Patent: October 1, 2019Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
-
Patent number: 10266574Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: June 24, 2014Date of Patent: April 23, 2019Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker